% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Giagkou:144973,
      author       = {Giagkou, Nikolaos and Höglinger, Günter U and Stamelou,
                      Maria},
      title        = {{P}rogressive supranuclear palsy.},
      journal      = {International review of neurobiology},
      volume       = {149},
      issn         = {0074-7742},
      address      = {Heidelberg [u.a.]},
      publisher    = {Elsevier, Acad. Press},
      reportid     = {DZNE-2020-00337},
      pages        = {49-86},
      year         = {2019},
      abstract     = {Progressive supranuclear palsy (PSP) is a neurodegenerative
                      disease characterized pathologically by 4 repeat tau
                      deposition in various cell types and anatomical regions.
                      Richardson's syndrome (RS) is the initially described and
                      one of the clinical phenotypes associated with PSP
                      pathology, characterized by vertical supranuclear gaze paly
                      in particular downwards, postural instability with early
                      falls and subcortical frontal dementia. PSP can manifest as
                      several other clinical phenotypes, including
                      PSP-parkinsonism, -pure akinesia with gait freezing,
                      -frontotemporal dementia, - corticobasal syndrome, -
                      speech/language impairment. RS can also have a pathologic
                      diagnosis other than PSP, including corticobasal
                      degeneration, FTD-TDP-43 and others. New clinical diagnostic
                      criteria take into account this phenotypic variability in an
                      attempt to diagnose the disease earlier, given the current
                      lack of a validated biomarker. At present, therapeutic
                      options for PSP are symptomatic and insufficient. Recent
                      large neuroprotective trials have failed to provide a
                      positive clinical outcome, however, have led to the design
                      of better studies that are ongoing and hold promise for a
                      neuroprotective treatment for PSP.},
      keywords     = {Humans / Supranuclear Palsy, Progressive: diagnosis /
                      Supranuclear Palsy, Progressive: drug therapy / Supranuclear
                      Palsy, Progressive: metabolism / Supranuclear Palsy,
                      Progressive: physiopathology},
      cin          = {AG Höglinger 1 ; AG Höglinger},
      ddc          = {610},
      cid          = {I:(DE-2719)1110002},
      pnm          = {344 - Clinical and Health Care Research (POF3-344)},
      pid          = {G:(DE-HGF)POF3-344},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31779824},
      doi          = {10.1016/bs.irn.2019.10.013},
      url          = {https://pub.dzne.de/record/144973},
}